BR112015021523A2 - composition of an acellular pertussis vaccine, and methods for vaccinating a subject against bordetella pertussis and for protecting a subject from pertussis - Google Patents

composition of an acellular pertussis vaccine, and methods for vaccinating a subject against bordetella pertussis and for protecting a subject from pertussis

Info

Publication number
BR112015021523A2
BR112015021523A2 BR112015021523A BR112015021523A BR112015021523A2 BR 112015021523 A2 BR112015021523 A2 BR 112015021523A2 BR 112015021523 A BR112015021523 A BR 112015021523A BR 112015021523 A BR112015021523 A BR 112015021523A BR 112015021523 A2 BR112015021523 A2 BR 112015021523A2
Authority
BR
Brazil
Prior art keywords
pertussis
subject
vaccinating
protecting
composition
Prior art date
Application number
BR112015021523A
Other languages
Portuguese (pt)
Other versions
BR112015021523A8 (en
Inventor
Theunis Poolman Jan
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of BR112015021523A2 publication Critical patent/BR112015021523A2/en
Publication of BR112015021523A8 publication Critical patent/BR112015021523A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1225—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

1 / 39 1 / 1 resumo “composiã‡ãƒo de uma vacina contra a tosse convulsa acelular, e, mã‰todos para vacinar um sujeito contra a bordetella pertussis e para proteger um sujeito da tosse convulsa” a invenã§ã£o se refere a uma composiã§ã£o de uma vacina contra a tosse convulsa acelular (ap) compreendendo como antã­genos da bordetella pertussis o toxoide da tosse convulsa (pt), hemaglutinina filamentosa (fha), e fã­mbrias dos tipos 2 e 3 (fim), e opcionalmente pertactina (prn), em que as fim estã£o presentes em uma quantidade de 12-100 âµg por dose humana.The invention does not refer to a vaccine composition against acellular pertussis (ap) comprising as bordetella pertussis antigens pertussis toxoid (pt), filamentous hemagglutinin (fha), and types 2 and 3 (end), and optionally pertactin (prn), wherein the ends are present in an amount of 12-100 µg per human dose.

BR112015021523A 2013-03-08 2014-03-06 composition of a vaccine against acellular pertussis, and uses of the composition and antigens of bordetella pertussis BR112015021523A8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361774993P 2013-03-08 2013-03-08
EP13169328 2013-05-27
PCT/EP2014/054379 WO2014135651A1 (en) 2013-03-08 2014-03-06 Acellular pertussis vaccine

Publications (2)

Publication Number Publication Date
BR112015021523A2 true BR112015021523A2 (en) 2017-07-18
BR112015021523A8 BR112015021523A8 (en) 2021-06-29

Family

ID=48470836

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015021523A BR112015021523A8 (en) 2013-03-08 2014-03-06 composition of a vaccine against acellular pertussis, and uses of the composition and antigens of bordetella pertussis

Country Status (22)

Country Link
US (2) US8916173B2 (en)
EP (1) EP2863943B1 (en)
JP (1) JP6282673B2 (en)
KR (1) KR102236498B1 (en)
CN (1) CN105007936B (en)
AP (1) AP2015008702A0 (en)
AU (1) AU2014224556B2 (en)
BR (1) BR112015021523A8 (en)
CA (1) CA2903937C (en)
CL (1) CL2015002513A1 (en)
DK (1) DK2863943T3 (en)
EA (1) EA030749B1 (en)
ES (1) ES2597832T3 (en)
IL (1) IL241271A (en)
MX (1) MX362793B (en)
MY (1) MY172181A (en)
NZ (1) NZ630868A (en)
PE (1) PE20151720A1 (en)
PH (1) PH12015501875A1 (en)
SG (1) SG11201506858SA (en)
TW (1) TWI630915B (en)
WO (1) WO2014135651A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2596919C2 (en) * 2015-01-16 2016-09-10 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Combined vaccine for preventing pertussis, diphtheria, tetanus
RU2626532C2 (en) * 2015-01-16 2017-07-28 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Combined vaccine to prevent whooping cough, diphtheria, tetanus, hepatitis and infections caused by type b haemophilus influenzae
KR102426041B1 (en) 2017-08-01 2022-07-29 주식회사 녹십자 Method for obtaining bordetella pertussis related protein comprising processes of freezing and thawing
KR102362777B1 (en) 2018-03-27 2022-02-15 주식회사 녹십자 Method for obtaining bordetella pertussis related proteins comprising affinity chromatography
EP3876982A1 (en) 2018-11-06 2021-09-15 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
CN111053898B (en) * 2019-12-26 2023-05-16 北京科兴中维生物技术有限公司 Vaccine composition and application thereof
JP2023517330A (en) * 2020-03-09 2023-04-25 ダイナヴァックス テクノロジーズ コーポレイション Active booster against tetanus, diphtheria, and pertussis
WO2024064579A1 (en) * 2022-09-20 2024-03-28 Ohio State Innovation Foundation Immunogenic proteins from bordetella pertussis

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4525349A (en) 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
GB8412207D0 (en) 1984-05-12 1984-06-20 Wellcome Found Antigenic preparations
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
GB8516442D0 (en) 1985-06-28 1985-07-31 Wellcome Found Cloned antigen
IT1187753B (en) 1985-07-05 1987-12-23 Sclavo Spa GLYCOPROTEIC CONJUGATES WITH TRIVALENT IMMUNOGENIC ACTIVITY
DE3528006A1 (en) 1985-08-05 1987-02-05 Degussa METHOD FOR PRODUCING EPOXY-ORGANOSILIZED COMPOUNDS
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
GB8601279D0 (en) 1986-01-20 1986-02-26 Public Health Lab Service Purification of pertussis antigens
DE3781541T2 (en) 1986-12-23 1993-05-06 Univ Leland Stanford Junior MODIFIED PERTUSSISTOXIN.
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP0299108B1 (en) 1987-07-17 1994-05-18 Rhein Biotech Gesellschaft für biotechnologische Prozesse und Produkte mbH DNA-molecules coding for FMDH control regions and structured gene for a protein having FMDH-activity and their uses
US7144576B1 (en) 1987-09-04 2006-12-05 Amgen, Inc. Modified pertussis toxin
KR0168039B1 (en) 1987-09-04 1999-01-15 로버트 디. 웨스트 Recombinant dna derived bordetella toxin subunit analogs
IT1223334B (en) 1987-11-02 1990-09-19 Sclavo Spa IMMUNOLOGICALLY ACTIVE POLYPEPTIDES WITH AN ALTERED TOXICITY USEFUL FOR THE PREPARATION OF AN ANTIPERTOX VACCINE
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
GB8807860D0 (en) 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA1341123C (en) 1988-10-27 2000-10-17 David A. Relman Filamentous hemagglutinin of b. pertussis
US5101014A (en) 1989-02-10 1992-03-31 United States Of America Process for the purification of a 69,000 da outer membrane protein of Bordetella pertussis
DE69022106T2 (en) 1989-04-28 1996-02-15 Sclavo Spa Pertussis toxin mutants, the same producing Bordetella strains and their use as a vaccine against pertussis.
GB8910570D0 (en) 1989-05-08 1989-06-21 Wellcome Found Acellular vaccine
JPH0832638B2 (en) 1989-05-25 1996-03-29 カイロン コーポレイション Adjuvant formulation comprising submicron oil droplet emulsion
GB8914122D0 (en) 1989-06-20 1989-08-09 Wellcome Found Polypeptide expression
DE69025375T2 (en) 1989-11-06 1996-08-01 Smithkline Beecham Biolog method
US5276142A (en) 1989-12-11 1994-01-04 American Cyanamid Company Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis
CY1935A (en) 1990-02-12 1991-02-07 Smithkline Beecham Biolog Novel vaccine and method therefor
GB9007657D0 (en) 1990-04-04 1990-05-30 Connaught Lab Purification of a pertussis outer membrane protein(omp69)
EP0484621A3 (en) 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US6444211B2 (en) 1991-04-03 2002-09-03 Connaught Laboratories, Inc. Purification of a pertussis outer membrane protein
AU662783B2 (en) 1992-01-08 1995-09-14 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Whooping cough vaccine
DE69324487T2 (en) 1992-05-06 1999-08-12 Harvard College RECIPTOR-BINDING REGION OF THE DIPHTHERIETOXIUS
DE69319728T2 (en) 1992-05-23 1999-02-04 Smithkline Beecham Biolog Combined vaccines that contain hepatitis B surface antigen and other antigens
DK0652758T3 (en) 1992-06-18 2000-05-08 Harvard College Diferitoxin vaccines
ATE254475T1 (en) 1993-09-22 2003-12-15 Jackson H M Found Military Med METHOD FOR ACTIVATION OF SOLUBLE CARBOHYDRATES BY USING NEW CYANYLATION REAGENTS TO PRODUCE IMMUNOGENIC CONSTRUCTS
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FI951970A (en) 1995-04-25 1996-10-26 Borealis As Olefin polymers containing polar groups and a process for their preparation
US5877298A (en) * 1995-05-04 1999-03-02 Connaught Lab Acellular pertussis vaccines and methods of preparing thereof
BR9608114A (en) 1995-05-04 2000-10-31 Connaught Lab Cellular pertussis vaccines and processes for preparing them
FR2734484B1 (en) 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc LIQUID VACCINE COMPOSITION AND MANUFACTURING METHOD
CA2259415A1 (en) * 1996-07-02 1998-01-08 Connaught Laboratories Limited Multivalent dtp-polio vaccines
GB9623233D0 (en) 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
US6475754B1 (en) 1999-05-14 2002-11-05 University Of Tennessee Research Corporation Polynucleotides encoding Bordatella bronchiseptica fimbrial proteins (FimN), vectors, and expression systems therefor
SK288007B6 (en) 2000-06-29 2012-10-02 Glaxosmithkline Biologicals S. A. Multivalent vaccine composition, process for its producing, and its use
EP1174505A1 (en) * 2000-06-30 2002-01-23 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur (Poly)peptides for the preparation of vaccines against Bordetella pertussis and/or Bordetella parapertussis, vaccines based upon such (poly)peptides, and antibodies against such peptides
GB0018031D0 (en) 2000-07-21 2000-09-13 Microbiological Res Authority Improvements relating to vaccines containing bordetella pertussis antigen
SE0202110D0 (en) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
SE0301998D0 (en) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
PT2097102E (en) 2006-09-07 2012-08-03 Glaxosmithkline Biolog Sa Combination vaccine having reduced polio virus antigen quantities
PE20100366A1 (en) 2008-10-24 2010-05-21 Panacea Biotec Ltd NOVEL COMPOSITIONS OF VACCINE WITH CELLULAR WHOOUS COUGH AS WELL AS THE METHOD FOR ITS ELABORATION
PL2454364T3 (en) 2009-07-16 2014-09-30 Crucell Holland Bv Production of polio virus at high titers for vaccine production
JP6191082B2 (en) 2011-03-02 2017-09-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Combination vaccine with lower dose of antigen and / or adjuvant

Also Published As

Publication number Publication date
WO2014135651A1 (en) 2014-09-12
AU2014224556A1 (en) 2015-09-17
US8916173B2 (en) 2014-12-23
US20150086586A1 (en) 2015-03-26
JP2016510056A (en) 2016-04-04
EA030749B1 (en) 2018-09-28
JP6282673B2 (en) 2018-02-21
CA2903937A1 (en) 2014-09-12
BR112015021523A8 (en) 2021-06-29
SG11201506858SA (en) 2015-09-29
MX2015011879A (en) 2016-01-08
EP2863943B1 (en) 2016-07-13
AU2014224556B2 (en) 2016-10-06
MY172181A (en) 2019-11-15
TWI630915B (en) 2018-08-01
ES2597832T3 (en) 2017-01-23
AP2015008702A0 (en) 2015-09-30
KR20150124973A (en) 2015-11-06
TW201440786A (en) 2014-11-01
EA201591663A1 (en) 2016-01-29
KR102236498B1 (en) 2021-04-06
US20140255446A1 (en) 2014-09-11
EP2863943A1 (en) 2015-04-29
CL2015002513A1 (en) 2016-05-27
MX362793B (en) 2019-02-13
PH12015501875A1 (en) 2015-12-07
CN105007936B (en) 2018-10-02
IL241271A (en) 2016-07-31
IL241271A0 (en) 2015-11-30
PE20151720A1 (en) 2015-12-10
CA2903937C (en) 2021-11-09
DK2863943T3 (en) 2016-11-07
CN105007936A (en) 2015-10-28
NZ630868A (en) 2017-02-24

Similar Documents

Publication Publication Date Title
BR112015021523A2 (en) composition of an acellular pertussis vaccine, and methods for vaccinating a subject against bordetella pertussis and for protecting a subject from pertussis
BR112018013387A2 (en) recombinant vaccination vector, mva virus, vaccine or pharmaceutical composition and kit
CL2019003264A1 (en) Formulations for vaccines against neoplasia and methods for preparing the same. (divisional request 201703151)
BR112017013891A2 (en) immunogenic compositions for use in pneumococcal vaccines
PE20151588A1 (en) VACCINE AGAINST DENGUE VIRUS
BR112013022397A2 (en) vaccines combined with lower doses of antigen and / or adjuvant
CR11122A (en) WATER OIL EMULSION INFLUENZA VACCINE
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
CL2015001900A1 (en) Vaccines with higher density of carbohydrate antigen and new saponin adjuvant.
ECSP14013201A (en) PARENTERAL FORMULATIONS OF VACCINES AGAINST NOROVIRUS
CL2011002639A1 (en) Bacterial strain of mycoplasma bovis attenuated avirulent; immunogenic composition that comprises it; and use to make a medicine for infections caused by m. bovis
BR112017003462A2 (en) attenuated bovine coronavirus, vaccine, and method of vaccination of a bovine.
MX2015007753A (en) Vaccine composition for naive subjects.
MX2016016746A (en) Dual adjuvant vaccine compositions, preparation and uses.
CO6361948A2 (en) USE OF MYCOPLASMA BOVIS ANTIGEN
BR112019003992A2 (en) neisseria meningitidis vaccine
BR112015005056A2 (en) combination vaccines with meningococcus serogroup b and d / t / p
AR108829A1 (en) VACCINE AGAINST INFECTIOUS BRONCHITIS VIRUS
BR112017004197A2 (en) Dengue virus disease vaccine compositions
UA114286C2 (en) Methods and compositions for vaccinating against staphylococcus aureus
CO2017007057A2 (en) Foot and mouth disease vaccine
MX2017013564A (en) Glucopyranosyl lipid a and peanut allergen formulations for sublingual administration.
NZ743977A (en) M hyo multivalent vaccine and uses thereof
UY35307A (en) TYPICAL ANTIFUNGICAL COMPOSITION FOR ONICOMYCOSIS TREATMENT
PL404247A1 (en) LOS oligosugar Bordetella pertussis and pertussis toxin and its use in the prevention and treatment of infections caused by Bordetella pertussis

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: JANSSEN VACCINES AND PREVENTION B.V (NL)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25G Requested change of headquarter approved

Owner name: JANSSEN VACCINES AND PREVENTION B.V. (NL)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements